Olaparib -modern approach to the treatment of BRCA-associated HER2-negative metastatic breast cancer. Clinical experience
- Authors: Lubennikova E.V1, Zhukova L.G2, Gordeeva O.O1, Drobot N.T.1, Kuznetsov A.V3, Ganshina I.P1
-
Affiliations:
- N.N. Blokhin National Medical Research Center of Oncology
- A.S. Loginov Moscow Clinical Research Center
- Clinical Hospital MEDSI
- Issue: Vol 28, No 7 (2021)
- Pages: 146-152
- Section: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/313192
- DOI: https://doi.org/10.18565/pharmateca.2021.7.146-150
- ID: 313192
Cite item
Open Access
Access granted
Abstract
Modern possibilities of molecular genetic diagnostics and advances in drug therapy for metastatic breast cancer (BC) have made it possible to personalize the treatment, thus improving its results. The use of PARP inhibitors in BRCA-associated BC is a priority option, which significantly improves the survival rates and quality of life of patients. The results of international studies are impressive, but there is still little experience with the use of PARP inhibitors in routine practice. This publication presents a clinical case of the successful use of olaparib (Linparza) in a young patient with metastatic HER2-negative BRCA-associated BC.
Keywords
Full Text
About the authors
E. V Lubennikova
N.N. Blokhin National Medical Research Center of Oncology
Email: lubennikova@yandex.ru
Moscow, Russia
L. G Zhukova
A.S. Loginov Moscow Clinical Research CenterMoscow, Russia
O. O Gordeeva
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
N. Ts Drobot
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
A. V Kuznetsov
Clinical Hospital MEDSIMoscow, Russia
I. P Ganshina
N.N. Blokhin National Medical Research Center of OncologyMoscow, Russia
References
- Gobbini E., Ezzalfani M., Dieras V., et al. Time trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort. Eur J Cancer. 2018;96:17-24. Doi: 10.1016/j. ejca.2018.03.015
- Schmid R, Adams S., Hugo H.S., et al. Atezolizumab and nab-paditaxel in advanced triple-negative breast cancer. N EnglJ Med 2018;3 79(2 2):210S-21. doi: 10.1056/NEJMoa1809615.
- Wooster R.r Weber B.L. Breast and ovarian cancer N Engl J Med. 2003;348(23):2339-47. doi: 10.1056/NEJMra012284.
- Wooster R., Bignell G., Lancaster J., et al. Identification of the breast cancer susceptibility gene BRCA2. Nature. 1995;378(6559):789-92. doi: 10.1038/378789a0.
- Miki Y, Swensen J., Shattuck-Eidens D., et al. / strong cansusceptibility gene BRCA1. Sci. 1994;266(5182):66-71. Doi: 10.1126/ science. 7545954.
- Jiang Y.Z., Ma D., Suo C, et al. Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. Cancer Cell. 2019;35(3):428-40.e5. doi: 10.1016/j.ccell.2019.02.001. strand break repair-independent role for В RCA 2 in blocking stalled replication fork degradation by MRE11. Cell. 2011;145(4):529-42. doi: 10.1016/j.cell. 2011.03.041.
- Schlacher K., Christ N., Siaud N., et at Double mutation and HER2-negative metastatic breast trends of overall survival among metastatic breast cancer patients in the real-life ESME cohort Eur J Cancer. 2018;96:17-24. Doi: 10.1016/j. ejca.2018.03.015
- Ramus S.J., Gayther S.A. The contribution of BRCA1 and BRCA2 to ovarian cancer. Mol Oncol. 2009;3(2):138-50. Doi: 10.1016/j. molonc.2009.02.001.
- Robson M., Im S.A., Senkus E., et al. Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N EnglJ Med. 2017;3 77(6/523-33. doi: 10.1056/NEJMoa1706450.
- Tung N.M., Im S.A., Senkus-Konefka E., et al. Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer (OlympiAD): Efficacy in patients with visceral metastases. J Clin Oncol. 2018;36(Suppl. 15/1052-52. doi: 10.1200/JC0.2018.36.15_ suppl. 1052.
- Robson M.E., Tung N., Conte P, et al. OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA cancer. Ann Oncol. 2019;30(4):558-66. doi: 10.1093/annonc/mdz012.
- Robson M., Ruddy K.J., Im S.A., et al. 4542 -OlympiAD: Health-related quality of life (HRQoL) in pa dents with HER 2- negative metastatic breast ca ncer (mBC) and a germline BRCA mutation (gBRCAm) receiving olaparib monotherapy vs standard singleagent chemotherapy treatment of physician's choice (TPC). Ann Oncol. 2017;28(Suppl. 5/S74-108. doi: 10.1093/annonc/mdx365.
- Gelmon K.A., Walker G.P, Fisher G.V., McCutcheon S. C. LUCY: A phase 11 lb, real-world study of olaparib in HER2-negative metastatic breast cancer patients with a BRCA mutation. Ann Oncol. 2018;29(Suppl. 8/VIII120. doi: 10.1093/annonc/mdy272.355.
- Richards S., Aziz N., Bale S., et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405-24. doi: 10.1038/gim.2015.30.
Supplementary files
